Bliive helps innovation-driven start-ups from their initial development and onwards to establish the identity with which they will grow.
Bliive offers its strategic and operational expertise first to companies in the biotech, healthcare, and well-being industries. Its network of experts can, however, be of help for any disruptive technology that needs market evangelization for its growth.
Bliive helps you consolidate your scientific foundation and communicate efficiently about your technologies.
Bliive helps you identify what makes your company unique and create the right messages to promote your innovations.
Bliive leverages its network of seasoned managers to help you evolve from small start-up to full-grown team, without losing your identity.
Contact our founding partner, Nathalie Compagnone, Ph.D and MBA, for an initial diagnosis of your organization at
Dr. Compagnone, formerly at executive positions in biotech companies dedicated to drug development in neurodegenerative diseases, offers her professional experience and continued training in Healthcare industry management. She has a double competency in science and business.
Dr. Compagnone is a trained neuroscientist, who received her Ph.D. in 1993 after completing an Engineering degree from ESA. She was the principal investigator of a research laboratory at the University of California, San Francisco (UCSF) prior to joining the pharmaceutical industry in 2004 to manage programs later bought by Roche. Dr. Compagnone is specialized in system biology, molecular & cellular imaging, and image analysis. She has also trained in business management and received a certificate in Bioentrepreneurship (CBE) from UCSF, followed by the completion of an executive MBA program from IAE (Aix-en-Provence), a mini-MBA in the management of innovation from Rutgers University, and modules from HEC executive education (Paris).
In 2007, Dr. Compagnone founded ICDD, a company that offered innovative decision tools enabling the optimization of development processes for health products, believing it would drive safer, more targeted medicine for patients. Using mitochondrial activity, ICDD helped the pharmaceutical and cosmetic industries test the efficacy and toxicity of products at a pre-clinical stage. A second business unit focused on modeling & diagnostic tool development in CNS diseases (AD and HD). Dr. Compagnone remained CEO and CSO of ICDD until its service unit was acquired by GeneStore France in 2019.